ESR1 and prostate carcinoma: Members of this list have previously been associated with prostate cancer, where decreased expression of ESR1 has been found to be particularly associated with hormone refractory disease [32], and PPARγ whose activity is regulated by direct binding of steroid and thyroid hormones, vitamins, lipid metabolites and xenobiotics and have been shown to participate in the development of the disease [33, 34].